Aliases & Classifications for Allergic Disease

MalaCards integrated aliases for Allergic Disease:

Name: Allergic Disease 12 15
Hypersensitivity 12 73 44 15 70
Allergic Hypersensitivity Disease 12
Allergic Disposition 70
Allergic Condition 70
Allergic Reaction 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1205
MeSH 44 D006967
NCIt 50 C3114
SNOMED-CT 67 257550005
ICD10 32 T78.40
UMLS 70 C0020517 C0851444 C1527304 more

Summaries for Allergic Disease

Disease Ontology : 12 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

MalaCards based summary : Allergic Disease, also known as hypersensitivity, is related to nut allergy and hypersensitivity reaction type iv disease, and has symptoms including nausea and vomiting, abdominal pain and pruritus. An important gene associated with Allergic Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lidocaine and Ertapenem have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and prostate, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 73 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...

Related Diseases for Allergic Disease

Diseases related to Allergic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1760)
# Related Disease Score Top Affiliating Genes
1 nut allergy 32.7 IL5 IL4 IL13 IGHE
2 hypersensitivity reaction type iv disease 32.6 TNF IL4 IL2 IFNG CXCL10
3 farmer's lung 32.4 TNF IL2 IGHE
4 erythema multiforme 32.2 TNF IL5 IL4 IL2 IFNG
5 drug allergy 32.2 IL5 IL4R IL13 IGHE
6 respiratory allergy 32.1 TSLP RNASE3 IL5 IL4R IL4 IL3
7 bronchiolitis obliterans 32.0 TNF IL13 IFNG
8 pulmonary sarcoidosis 32.0 TNF IL2 IFNG
9 latex allergy 32.0 TNF RNASE3 IL5 IL4 IL13 IGHE
10 allergic asthma 32.0 TSLP RNASE3 IL9 IL5 IL4R IL4
11 cardiac sarcoidosis 32.0 TNF IL5 IFNG
12 sarcoidosis 1 32.0 TNF IL9 IL2 IL13 IFNG CXCL10
13 metal allergy 31.9 IL4 IL2
14 cryoglobulinemia 31.9 TSLP TNF IFNG CXCL10
15 churg-strauss syndrome 31.9 TNF RNASE3 IL5 IL3 IL2 CCL11
16 bullous pemphigoid 31.9 TNF RNASE3 IL5 IL4 IL13 IGHE
17 toxicodendron dermatitis 31.9 TNF IL2
18 ige responsiveness, atopic 31.7 RNASE3 IL5 IL4R IL4 IL13 IGHE
19 autoimmune disease of central nervous system 31.7 TNF IL5 IL4 IL2 IL13 IFNG
20 rhinitis 31.7 TSLP TNF RNASE3 IL9 IL5 IL4R
21 allergic rhinitis 31.7 RNASE3 IL9 IL5 IL4R IL4 IL13
22 dermatitis, atopic 31.6 TSLP TNF SYK RNASE3 IL9 IL5
23 interstitial lung disease 31.6 TNF IL5 IL4 IL13 IFNG CXCL10
24 dermatitis 31.6 TSLP TNF RNASE3 IL5 IL4R IL4
25 food allergy 31.6 TNF RNASE3 IL5 IL4R IL4 IL13
26 pollen allergy 31.5 RNASE3 IL5 IL4R IL3 IL13 IGHE
27 myocarditis 31.4 TNF IL4 IL2 IFNG CD86
28 diarrhea 31.3 TNF IL5 IL2 IL13 IFNG
29 pulmonary fibrosis, idiopathic 31.3 TSLP TNF IL9 IL5 IL4 IL13
30 leprosy 3 31.3 TNF IL5 IL4 IL2 IL13 IFNG
31 purpura 31.2 TNF IL4 IFNG
32 penicillin allergy 31.2 IL4R IL4 IL13 IGHE IFNG
33 urticaria 31.2 TNF SYK RNASE3 IL5 IL4 IL3
34 pneumonia 31.2 TNF IL5 IL4 IL13 IFNG CXCL10
35 leishmaniasis 31.2 TNF IL5 IL4 IL2 IL13 IFNG
36 cytokine deficiency 31.2 IL9 IL5 IL13
37 alopecia 31.2 TNF IL4 IL2 IFNG
38 schistosomiasis 31.1 TNF RNASE3 IL9 IL5 IL4 IL2
39 conjunctivitis 31.1 TNF RNASE3 IL5 IL4 IL2 IL13
40 stomatitis 31.1 TNF IL4 IL2 IFNG
41 candidiasis 31.1 TNF IL4 IL2 IFNG
42 pulmonary tuberculosis 31.1 TNF IL4 IL2 IFNG
43 respiratory failure 31.1 TNF RNASE3 IL5 IL13 EPX CXCL10
44 irritant dermatitis 31.0 TSLP TNF IL4 CXCL10
45 crohn's disease 31.0 TNF IL4 IL2 IL13 IFNG
46 gastroesophageal reflux 31.0 TNF IL5 IL4 CCR3 CCL11
47 milk allergy 31.0 TNF RNASE3 IL9 IL5 IL4 IL13
48 brucellosis 31.0 TNF IL4 IL2 IL13 IFNG CD86
49 thyroiditis 31.0 TNF IL4 IL2 IFNG CXCL10
50 allergic conjunctivitis 31.0 TNF RNASE3 IL5 IL4 IL2 IL13

Graphical network of the top 20 diseases related to Allergic Disease:



Diseases related to Allergic Disease

Symptoms & Phenotypes for Allergic Disease

UMLS symptoms related to Allergic Disease:


nausea and vomiting; abdominal pain; pruritus; syncope; stridor; tinnitus; snoring; sore throat; exanthema; coughing; vertigo/dizziness; equilibration disorder; signs and symptoms of ill-defined conditions; (non-specific) malaise and fatigue; injection site hypersensitivity; fever of unknown origin

MGI Mouse Phenotypes related to Allergic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 CCL11 CCR3 CD86 CXCL10 EPX FCER2
2 homeostasis/metabolism MP:0005376 10.03 CCR3 CD86 CXCL10 EPX FCER2 IFNG
3 digestive/alimentary MP:0005381 10.02 FCER2 IFNG IL13 IL2 IL4 IL4R
4 immune system MP:0005387 9.89 CCL11 CCL22 CCR3 CD86 CXCL10 EPX
5 respiratory system MP:0005388 9.36 CCL11 CCR3 IFNG IL13 IL2 IL4

Drugs & Therapeutics for Allergic Disease

Drugs for Allergic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 773)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
3
Dapsone Approved, Investigational Phase 4 80-08-0 2955
4
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
5
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
6
Linagliptin Approved Phase 4 668270-12-0 10096344
7
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Budesonide Approved Phase 4 51333-22-3 63006 5281004
10
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
11
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
14
Montelukast Approved Phase 4 158966-92-8 5281040
15
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
16
sodium fluoride Approved Phase 4 7681-49-4
17
Clevidipine Approved, Investigational Phase 4 167221-71-8
18
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
19
Levocetirizine Approved Phase 4 130018-77-8 1549000
20
Clarithromycin Approved Phase 4 81103-11-9 84029
21
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Glycerol Approved, Investigational Phase 4 56-81-5 753
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Capsaicin Approved Phase 4 404-86-4 1548943
26
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
27
carbamide peroxide Approved Phase 4 124-43-6
28
Cetirizine Approved Phase 4 83881-51-0 2678
29
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
30
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
31
Dimenhydrinate Approved Phase 4 523-87-5 441281
32
Magnesium oxide Approved Phase 4 1309-48-4 14792
33
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
34
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
35
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
36
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
37
Zoledronic Acid Approved Phase 4 118072-93-8 68740
38
Liraglutide Approved Phase 4 204656-20-2 44147092
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Ofloxacin Approved Phase 4 82419-36-1 4583
41
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
42
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
43
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
44
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
45
Etodolac Approved, Investigational, Vet_approved Phase 4 41340-25-4 3308
46
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
47
Adapalene Approved Phase 4 106685-40-9 60164
48
Benzoyl peroxide Approved Phase 4 94-36-0 7187
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309

Interventional clinical trials:

(show top 50) (show all 1727)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
2 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
3 Clinical Efficacy of Giomer Versus Sodium Fluoride Varnish for Management of Hypersensitivity: Randomized Control Trail Unknown status NCT03818945 Phase 4 shofu PRG barrier coat;Sodium fluoride varnish
4 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
5 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
6 Fludrocortisone's Test in the Identification of Salt Sensitivity Unknown status NCT01453959 Phase 4 Fludrocortisone
7 Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome. Unknown status NCT01871883 Phase 4
8 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
9 A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients Unknown status NCT01431859 Phase 4
10 Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals Unknown status NCT01253928 Phase 4 Pioglitazone
11 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Unknown status NCT03917784 Phase 4 Curcumin;Starch
12 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study Unknown status NCT02550093 Phase 4 Normal Saline;Oxytocin
13 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
14 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
15 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity Completed NCT00340080 Phase 4 Abacavir
16 The Prevention of Pain Associated With Rocuronium Injection: Effect of Pretreatment With Acetaminophen and Lidocaine Completed NCT02524743 Phase 4 acetaminophen;Lidocaine
17 Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction? Completed NCT00716963 Phase 4 Fluticasone propionate (Flovent Diskus) 250 mcg;budesonide 400 mcg
18 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE) Completed NCT01121458 Phase 4 Clevidipine
19 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
20 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Completed NCT01966640 Phase 4
21 The Role of Nonspecific Immune Response of the Airway Mucosa in Children With Chronic Rhinosinusitis and Asthma Completed NCT03011632 Phase 4 Mometasone Nasal;placebo mometasone
22 Phase 4 Study: Milk Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Completed NCT01361347 Phase 4
23 Integrated Approaches to Food Allergen and Allergy Risk Management: iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Completed NCT02552537 Phase 4 Omeprazole;Placebo
24 Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study Completed NCT01618929 Phase 4 Montelukast
25 Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study Completed NCT02111512 Phase 4 Administration of Live attenuated influenza vaccine (LAIV)
26 Evaluating Remineralizers and Desensitizers Agents in Dental Bleaching Treatment: in Vitro and in Vivo Study Completed NCT02316080 Phase 4
27 An Exploratory Clinical Study to Evaluate the Efficacy of Two Currently Marketed Toothpastes Containing Different Concentrations of a Tubule Occlusion Agent Completed NCT01075256 Phase 4
28 A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation Completed NCT00359138 Phase 4 desloratadine;levocetirizine;Desloratadine placebo tablet;Levocetirizine placebo capsule
29 Clinical, Controlled, Double-blind Study on the Effect of Whitening Dentifrices on Tooth Color and Tooth Sensitivity Completed NCT02483013 Phase 4
30 Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial Completed NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
31 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
32 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
33 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
34 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
35 Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02773758 Phase 4
36 A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02731833 Phase 4
37 A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02923895 Phase 4
38 An 8-Week Clinical Study to Evaluate the Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Non-surgical Periodontal Treatment: Randomized Clinical Trial Completed NCT02461030 Phase 4 In-office and at home Colgate sensitive pro-relief - CSPR;In-office Villevie® prophy paste + Colgate Toothpaste
39 Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery: A Randomised Doubled-blinded Control Study Completed NCT01774084 Phase 4
40 Effects of Desensitizing Dentifrices on the Reduction of Pain Sensitivity Caused by In-office Dental Whitening: Double Blind Controlled Clinical Study Completed NCT03019224 Phase 4 Hydrogen peroxide
41 Sensitivity of Electrocardiogram on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine: a Study in Children of Different Age Completed NCT01091766 Phase 4 intravenous injection of test solution;intravenous injection of test solution;intravenous injection of test solution
42 A Double Blind Randomized Control Trial to Study the Effect of Long Term Vitamin D Supplementation on Peripheral Insulin Sensitivity in Apparently Healthy Middle Aged Centrally Obese Adults Completed NCT01052181 Phase 4 Cholecalciferol;placebo
43 TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients Completed NCT02511535 Phase 4
44 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Completed NCT01475513 Phase 4 Ortho Cyclen®
45 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
46 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
47 Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) Completed NCT00154271 Phase 4 Valsartan, Valsartan HCT
48 Phase 4 Study of the Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction Completed NCT01205347 Phase 4 Simvastatin 80mg;Simvastatin 10mg
49 Combined Bleaching Technique: Efficacy and Tooth Sensitivity - A Randomized, Double Blind Clinical Trial Completed NCT03089216 Phase 4 8% arginine and calcium carbonate
50 Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity Completed NCT00263549 Phase 4

Search NIH Clinical Center for Allergic Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Cochrane evidence based reviews: hypersensitivity

Genetic Tests for Allergic Disease

Anatomical Context for Allergic Disease

MalaCards organs/tissues related to Allergic Disease:

40
Skin, T Cells, Prostate, Breast, Spinal Cord, Eye, Liver

Publications for Allergic Disease

Articles related to Allergic Disease:

(show top 50) (show all 35921)
# Title Authors PMID Year
1
IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. 61 54
20357258 2010
2
Genetic determinants of both ethanol and acetaldehyde metabolism influence alcohol hypersensitivity and drinking behaviour among Scandinavians. 54 61
20205700 2010
3
Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? 61 54
19563991 2009
4
Hypersensitivity to proton pump inhibitors: lansoprazole-induced Kounis syndrome. 61 54
18378022 2009
5
Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. 61 54
19473578 2009
6
Clinical immunotoxicity of therapeutic proteins. 54 61
19040329 2008
7
CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. 61 54
18005225 2008
8
Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 61 54
17873578 2007
9
[Type IV of hypersensitivity and its subtypes]. 54 61
18409354 2007
10
Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. 54 61
17008937 2006
11
Abacavir hypersensitivity reaction in primary HIV infection. 54 61
16816555 2006
12
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. 61 54
16393267 2006
13
[Level of interleukin-12 and interferon gamma in blood serum of children with neoplasms and allergy]. 54 61
16521418 2005
14
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. 61 54
15867870 2005
15
Anti-IgE antibodies for the treatment of asthma. 61 54
15591885 2005
16
The application of a monoclonal antibody to CD62L on paraffin-embedded tissue samples in the assessment of the cutaneous T-cell infiltrates. 54 61
15660650 2005
17
Anti-IgE therapy. 61 54
15474858 2004
18
Vaccination with genetically engineered allergens prevents progression of allergic disease. 54 61
15310844 2004
19
Isodon japonicus decreases immediate-type allergic reaction and tumor necrosis factor-alpha production. 54 61
15286441 2004
20
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. 54 61
15379589 2004
21
The mast cell: an antenna of the microenvironment that directs the immune response. 61 54
14726495 2004
22
Quantitative assessment of immediate cutaneous hypersensitivity in a mouse model exhibiting an IgE response to Timothy grass allergens. 54 61
14646968 2003
23
Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? 54 61
14677170 2003
24
Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. 61 54
12974198 2003
25
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. 61 54
12706535 2003
26
Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. 54 61
12734217 2003
27
L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. 61 54
12682269 2003
28
Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. 61 54
12456938 2002
29
Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. 54 61
11716123 2001
30
The role of immunoglobulin E in allergy and asthma. 54 61
11704610 2001
31
Phenotypic characterization of human CD4+ regulatory T cells obtained from cutaneous dinitrochlorobenzene-induced delayed type hypersensitivity reactions. 61 54
11511310 2001
32
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. 61 54
11294926 2001
33
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 54 61
11261930 2001
34
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. 61 54
11085746 2000
35
Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. 61 54
10994772 2000
36
Unique mechanistic features of allergic rhinitis. 61 54
10856164 2000
37
Identification and initial characterization of four novel members of the interleukin-1 family. 61 54
10744718 2000
38
Regulation of B lymphocyte differentiation. 61 54
10795645 2000
39
Il-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. 54 61
10821462 2000
40
Use of alkaline rinsing solution to prevent hypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. 61 54
10626828 1999
41
The effects of dexamethasone, cyclosporine, and vitamin D(3) on the activation of dendritic cells stimulated by haptens. 61 54
10552213 1999
42
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. 61 54
10480916 1999
43
Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. 61 54
10027949 1999
44
Regulation of FcepsilonARI synthesis in human eosinophils. 54 61
10224469 1999
45
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 54 61
10458510 1999
46
Cytokines and allergic diseases: clinical aspects. 54 61
9876771 1998
47
Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. 54 61
9500755 1998
48
Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. 54 61
9365117 1997
49
Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease. 54 61
9059357 1997
50
Antiallergic properties of antihistamines. 54 61
8939275 1996

Variations for Allergic Disease

Expression for Allergic Disease

Search GEO for disease gene expression data for Allergic Disease.

Pathways for Allergic Disease

Pathways related to Allergic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF SYK RNASE3 IL9 IL5 IL4R
2
Show member pathways
13.9 TNF IL9 IL5 IL4R IL4 IL3
3
Show member pathways
13.76 TSLP TNF IL9 IL5 IL4R IL4
4
Show member pathways
13.63 TNF IL9 IL5 IL4R IL4 IL3
5
Show member pathways
13.52 TNF SYK IL9 IL5 IL4R IL4
6
Show member pathways
13.42 TNF IL9 IL5 IL4R IL4 IL3
7
Show member pathways
13.24 TNF SYK IL4R IL4 IL2 IFNG
8
Show member pathways
13.08 SYK IL9 IL4R IL4 IL3 IL2
9
Show member pathways
13.02 TNF SYK IL4R IL4 IL3 IL2
10 12.93 IL5 IL4R IL4 IL3 IL2 IL13
11
Show member pathways
12.88 TNF SYK IL2 IFNG FCER2 CXCL10
12
Show member pathways
12.8 TNF IL9 IL4R IL4 IL2
13
Show member pathways
12.79 TNF SYK IL4R IL4 IL2 IGHE
14
Show member pathways
12.78 TNF RNASE3 IL9 IL5 IL4 IL3
15
Show member pathways
12.75 TNF IL5 IL4R IL4 IL2 IL13
16
Show member pathways
12.71 TNF SYK IL5 IL4 IL3 IL13
17
Show member pathways
12.69 TNF IL9 IL5 IL4 IL2 IFNG
18 12.69 TNF SYK IL4 IL3 IL2 IFNG
19
Show member pathways
12.64 TNF SYK IL9 IL5 IL4R IL4
20
Show member pathways
12.62 TNF SYK IL4 IL3 IL2 IFNG
21
Show member pathways
12.55 TSLP IL9 IL5 IL4R IL4 IL3
22
Show member pathways
12.5 TNF IL5 IL4 IL13 IFNG CXCL10
23
Show member pathways
12.47 IL4R IL4 IGHE FCER2 CCL11
24
Show member pathways
12.46 TNF IL2 CXCL10 CCR3 CCL22 CCL11
25
Show member pathways
12.42 TNF IL9 IL5 IL4 IL3 IL2
26
Show member pathways
12.35 TNF IL4 IL2 IFNG
27
Show member pathways
12.28 TNF IL4 IFNG CXCL10 CCL11
28
Show member pathways
12.24 TNF SYK IL2 CCL22
29
Show member pathways
12.21 SYK IL3 CD86 CCR3
30
Show member pathways
12.18 SYK IL5 IL3 IL2
31 12.14 TNF IL4 IL2 IFNG CXCL10
32 12.12 TNF IL5 IL4 IL3 IL2 IFNG
33 12.09 TNF IL5 IL4R IL4 IL3 FCER2
34 12.09 TNF IL4R IL4 IL13 IGHE FCER2
35
Show member pathways
11.96 TNF IL5 IL4 IL3 IL2 IFNG
36 11.95